# **Coagulation Disorders**

#### **Basic Definitions**

### • <u>Ecchymosis</u>

- o Bruise
- Most common complication during blood collection
- o Leakage of small amount of fluid around tissue
- Prevented by direct pressure

### Syncope

- o Fainting
- o 2nd most common complication

#### Hematoma

- o Leakage of large amount of fluid around puncture site
- Swelling

#### Petechiae

- Small red spots
- o Pinpoint size
- o Indicate small amount of blood escape into epithelium

### • <u>Purpura</u>

- o Purple skin discoloration
- o 1 cm or greater in diameter
- o seen with mucocutaneous bleeding

### • Telangiectasia

- o Permanent dilation of small blood vessels
- o Focused red lesions in skin or mucous membrane
- o fragile
- o Telangiectasis
- o Cherry-red hemangiomas
- o Louis-Bar

### • Angioma

- o tumor made up of blood vessels or lymph vessels
- o 2-6 mm
- o usually seen on trunk

### • <u>Hematur</u>ia

- o Blood in urine
- Epistaxis
  - o Nose bleed

# Hemorrhagic Coagulation Disorders

- Bleeding from multiple sites, recurring and spontaneous, or bleeding which requires intervention is evidence of a disorder or primary or secondary hemostasis
- Soft Tissue Hemorrhage: acquired or congenital plasma procoagulant deficiencies
  - Anatomic bleeding
  - o Most are internal with few visible signs
- <u>Hemarthroses</u>: joint bleeds
  - Swelling and acute pain
  - o Can cause permanent cartilage damage
- Mucocutaneous hemorrhage:
  - o Purpura
  - o Petechiae
  - Ecchymoses
  - o Menorrhagia
  - o Bleeding from gums
  - o Epistaxis
  - o Tends to be associated with:
    - thrombocytopenia
    - qualitative platelet disorders
    - vWD
    - scurvy
    - telangiectasia

### **Acquired Hemorrhagic Disorders**

- Most are secondary to chronic disease
- 1. Trauma-Induced Coagulopathy
  - Accounts for most instances of fatal hemorrhage
  - Triggered by the combination of injury-related acute inflammation, hypothermia, acidosis and hypoperfusion (systemic shock)
  - A. Massive Transfusion
    - a. Massive hemorrhage defined as:
      - i. Blood loss exceeding total blood volume within 24 hours
      - ii. Loss of 50% of blood volume within a 3-hour period
      - iii. Blood loss exceeding 150mL/min
      - iv. Blood loss that necessitates plasma and platelet transfusion
  - B. Plasma donation
    - a. New term is FP-24, moving away from previous term of FFP
  - C. Platelet Concentration
    - a. Usually only when platelet count fall bellows 50,000/uL
  - D. Concentrates

#### 2. Liver Disease

- Produces nearly all plasma coagulation factors and regulatory proteins
- Causes of suppression
  - o Hepatitis
  - o Cirrhosis
  - Obstructive jaundice
  - o Disorder of bilirubin metabolism
- Suppression of hepatocytes which will reduce concentrations or function of plasma coagulation factors to less than hemostatic levels (<40 units/dL)</li>
- Affects production of vitamin K dependent factors (II, VII, IX, X, C, S, Z)
  - VII first to show decreased activity
    - ½ life = 6 hours
- Declining factor V is specific marker of liver disease
  - o Differentiates vitamin K deficiency from liver disease (FV is not Vit. K Dependent)
- Decrease of fibrinogen < 100 mg/dL is a mark of liver failure
- Dysfibrinogenemia is seen in moderate liver disease
  - o Prolonged PT and RT
- vWF, VIII, XIII can be normal or elevated
- Thrombocytopenia occurs in 1/3 of the cases of liver disease
- Alcohol toxicity suppresses platelet production
- DIC in Liver Disease
  - Significant complication of liver disease
  - o Decreased production of AT, protein C, or protein S and release of procoagulants
  - Liver does not clear these procoagulants
  - Acute
    - PT, PTT, TT prolonged
    - Fibrinogen < 100 mg/dL</li>
    - Increased FDPs
  - Chronic and compensated
    - Abnormal D-dimer
- Laboratory Testing
  - o Factor V and VII assays
    - Differentiate vitamin K deficiency and liver disease
  - Confirmation of systemic fibrinolysis
    - Plasminogen deficiency
    - Increased D-dimer / FDPs
  - Reptilase time
    - Confirms dysfibrinogenemia (significantly prolonged)
- 3. Renal Failure and Hemorrhage
  - Chronic renal failure associations
    - Platelet dysfunction
    - Mucocutaneous bleeding
    - Acute GI bleeding
      - Decreased PLT adhesion/aggregation
      - Decreased RBC mass and thrombocytopenia

- Hemostasis Activation Syndromes
  - o Deposits fibrin into renal microvasculature which reduces glomerular filtration
    - DIC
    - HUS
    - TTP
  - Cause thrombocytopenia → bleeding
  - PT and PTT are expected to be normal
  - Bleeding time may be prolonged
- Nephrotic Syndrome
  - o Increased glomerular permeability
  - Associations
    - Amyloidosis
    - Diabetic glomerulosclerosis
    - SLE
    - Glomerulonephritis
    - Renal vein thrombosis
  - o LMW proteins and procoagulants found in urine
  - o Coagulation factors II, VII, IX, X, XII, antithrombin and protein C been found in the urine

### 4. Vitamin K Deficiency

- γ-carboxylation cycle is interrupted
- Causes
  - Biliary duct obstruction
  - Fat malabsorption
  - Chronic diarrhea
  - o Broad spectrum antibiotics that disrupt gut flora
- Hemorrhagic Disease of Newborn
  - o Breast feeding prolongs deficiency
- Antagonists
  - Warfarin
  - o Coumadin
  - o Disrupt vitamin K epoxide reductase and quinone reductase reactions → release of dysfunctional *des-gamma-carboxyl prothrombin* (VII, IX, X, C, S)
    - These inactive forms are called PIVKA factors
      - Proteins Induced by Vit. K Antagonists
- Lab Findings
  - Prolonged PT
  - o PTT can be normal or prolonged
  - Mixing study yields normal results
  - o Decreased factor VII (followed by IX, X and II)

#### 5. Acquired Anti-VIII Inhibitor and Hemophilia

- Anti-VIII is most common acquired autoantibody
  - o Highest risk when > 60 years of age or women 2-5 months pregnant
- Lab findings in acquired hemophilia
  - o Prolonged PTT w/likely normal PT, TT

- Mixing study
  - Corrects on initial
  - Can be prolonged with incubation at 37 C
    - IgG isotype (time and temp dependent)
- Type I kinetics: linear in vitro neutralization over 1-2 hours
  - o complete inactivation
- Type II kinetics: early rapid loss with residual activity
  - o Intermediate equilibrium
- Quantified by Bethesda titer
- Treated with DDAVP or rFVIIIa

### 6. Acquired vWD

- Manifests w/moderate to severe mucocutaneous bleeding and no family history of bleeding
- Associations
  - Hypothyroidism
  - o Lymphoproliferative or myeloproliferative disorders
  - o Wilms tumor (nephroblastoma)
  - o Congenital heart disease
  - o HUS
  - o Pesticide exposure
- Prolonged PTT is severe (↓VWF and FVIII)
- Diminished ristocetin cofactor/VWF activity/VWF antigen

### **Congenital** Hemorrhagic Disorders

- 1. vWD
  - mucocutaneous bleeding disorder
  - caused by quantitative or qualitative abnormality of vWF
    - vWF basics
      - Main function is platelet adhesion to subendothelial collagen in high shear stress
      - Synthesized in ER and stored in weibel-palade bodies of endothelial cells and platelet  $\alpha$ -granules
    - o abnormality causes  $\downarrow$  platelet adhesion impaired primary hemostasis
  - most prevalent congenital bleeding disorder!
  - normal plasma level 0.5 1 mg/dL
    - o levels are normally lowest in O and highest in AB blood types
  - Domain A
    - o binding site for GP Ib/V/IX and supports collagen receptor site
  - Domain C
    - o provides a site that binds platelet receptor GPIIb/IIIa
  - Domain D
    - o binds factor VIII
- 2. Hemophilia A (classic)
  - Congenital single factor deficiency marked by anatomic soft tissue bleeding
  - 85% of all hemophiliacs
  - Factor VIII deficiency
    - Factor VIII deteriorates ~5% per hour at RT in vitro

- X chromosome abnormality
- Male hemizygotes experience anatomic bleeding
  - o Females are carriers
- All sons of hemophiliac men are normal if non-carrier mom
  - o Daughters are carriers
- 30% arise from spontaneous germline mutations (no family history)
- Rare symptomatic females
  - o True homozygosity or double heterozygosity
  - o Extreme lyonization
    - Disproportional inactivation of X chromosome with normal gene
- Factor VIII inhibitor in about  $\sim$ 30% of sever hemophilia cases (3% in moderate cases)
- Clinical manifestations
  - Deep muscle and joint hemorrhage
  - Hematomas
  - Wound oozing
  - o Bleeding into CNS, GI, kidneys
  - o Inflammation with chronic joint bleeds
  - Cranial bleeds → neurological symptoms
- Severity is *inversely* proportional to factor VIII activity
  - o <1% activity: severe</p>
  - o 1-5%: moderate
  - o 5-40%: mild
    - hemorrhage follows significant trauma
- 70% cases treated before 1984 were HIV (+) or died from AIDS
- Lab Findings
  - o Prolonged PTT
  - $\circ$  90% of female carriers are detected using the ratio of factor VIII activity to vWF antigen (VWF unaffected by  $\downarrow$  FVIII)
    - ratio below normal lower limit → carrier
  - o If FVIII level is >30%, no inhibitor is likely
  - o If FVIII level is <30%, mixing study is needed
    - Bethesda Assay (Nijmegen-Bethesda)
      - o If inhibitor is suggested
      - Normal plasma providing 100 units/dL factor activity mixed at increasing dilutions (decreasing conc.) in a series of tubes with full-strength patient plasma
      - The FVIII assays are performed and the results of the dilutions are expressed as titer (BU)
- 3. Hemophilia B-Factor IX deficiency
  - Christmas disease
  - ~14% hemophilia
  - PTT prolonged
  - Inhibitors present in ~3%
- 4. Hemophilia C (Rosenthal Syndrome)
  - Factor IX Deficiency

## 5. Factor V deficiency

- Prolonged bleeding
- PT and PTT prolonged
- DRVVT prolonged

# 6. Factor X deficiency

- PT and PTT prolonged DRVVT prolonged

## 7. Factor XIII deficiency

- Weak clot; dissolves ~2 hours in 5 M urea
- Normal PT, PTT, TT

# Vascular Disorders

### **Hereditary** Vascular Disorders

- 1. Telangiectasis/Rendu-Weber-Osler syndrome
  - Thin walled blood vessels with discontinuous endothelium
  - Inadequate smooth muscle and elastin
  - Telangiectasia on face, lips, tongue, nasal mucosa, fingers, toes, trunk
  - Lesions blanch with pressure
  - Manifests at puberty
  - Epistaxis is universal finding
  - Symptoms worsen with age
  - Normal bleeding time
  - Diagnosis: characteristic skin/mucous lesions
- 2. Kasabach-Merritt/hemangioma thrombocytopenia
  - Present at birth
  - Visceral or subcutaneous hemangiomas
    - o May become engorged with blood
  - DIC
  - Microangiopathic hemolytic anemia
- 3. Ehlers-Danlos
  - Hyperextensible skin
  - Hypermobile joints
  - Joint laxity
  - Fragile tissues
  - Bleeding tendency
  - Defects in collagen
    - Structure
    - o Production
    - Cross-linking
      - → inadequate connective tissue
  - (+) tourniquet test and prolonged bleed time

### **Acquired Vascular Disorders**

- 1. Allergic Purpura/Henoch-Schonlein
  - Characterized by skin rash and edema
  - Transient arthralgia
  - Nephritis
  - Abdominal pain
  - Palpable purpura
    - o Feet
    - Elbows
    - Knees
    - o Buttocks

- o Chest
- Children 2-7 years
  - o Predominates in boys
- Sudden onset following upper respiratory infection
- Proteinuria and hematuria
- Elevated WBC and ESR
- Normal hemostasis testing

## 2. Amyloidosis

- Deposition of abnormal quantities of amyloid in tissues
- Clinical presentation
  - o Purpura
  - o Hemorrhage
  - o Thrombosis

### 3. Senile purpura

- Elderly males
- Lack of collagen
- Flat dark blotches

# 4. Drug induced purpura

- Warfarin
- Barbiturates
- Diuretics
- Sulfonamides
- Iodides
- Massive generalize petechial eruptions

# Qualitative Platelet Disorders

### **Disorders of Adhesion Receptors**

- 1. Bernard Soulier
  - Giant platelets Syndrome
  - Manifested in infancy or childhood
  - Characteristics
    - Ecchymoses
    - Epistaxis
    - o Gingival bleeding
    - Prolonged bleeding
    - o Thrombocytopenia
    - o Decreased platelet survival
    - Inability to adhere to subendothelium
  - GP Ib/IX/V is missing or dysfunctional (Autosomal recessive)
    - Most frequently involves defect in Ib synthesis or expression
      - Contains binding sites for vWF and thrombin
    - In contrast to VWD, this abnormality cannot be corrected by the addition of normal plasma or cryoprecipitate (defect resides in the platelets)
  - No aggregation with ristocetin
    - o Normal response to ADP, EPI, collagen, and arachidonic acid
- 2. Von Willebrand Disease
- 3. Acquired defects of platelet adhesion
  - Myeloproliferative and lymphoproliferative disorders
  - Antiplatelet antibodies
  - Cardiopulmonary bypass surgery
  - Chronic Liver Disease
  - Drug-induced membrane modification

### **Disorders of Platelet Aggregation**

- 1. Glanzmann Thrombasthenia
  - Heterozygotes are normal
  - Homozygotes
    - Severe bleeding problems
  - Neonatal or infancy
  - Manifestations
    - Epistaxis
    - Gingival bleeding
    - o Disabling hemorrhage
    - o Petechiae
    - o Purpura
    - o Menorrhagia
    - GI bleeding
    - Hematuria
  - Deficiency or abnormality of GP IIb/IIIa (no fibrinogen binding)
    - defect in platelet plug formation

- Lab findings
  - Normal platelet count and morphology
  - Markedly prolongs bleeding time
  - Lack of aggregation with all platelet activating agents
  - Ristocetin induced binding to vWF is normal
- 2. Hereditary afibrinogenemia
- 3. Acquired defects of platelet aggregation
  - acquired von Willebrand disease
  - acquired uremia

### **Disorders of Platelet Secretion**

- 1. Storage Pool diseases
  - a. Dense Granule Deficiency
    - Non-albinos
      - Normal levels of granules
      - Defect in ability to package → serotonin accumulation
    - Albinism
      - Easy bruising
      - Mild bleeding
    - Lack of aggregation caused by lack of ADP secretion
      - o Hermansky-Pudlak
      - o Chediak-Higashi
      - o Wiskott Alderich
      - o TAR (Thrombocytopenia with Absent Radii Syndrome)
  - b. Alpha Granule Deficiency
    - i. Gray platelet syndrome
      - Mild bleeding tendency
      - Prolonged bleeding time
      - Moderate thrombocytopenia
      - Fibrosis of marrow
      - Large platelets
    - ATP release in response to thrombin is reduced
- 2. Thromboxane Pathway Disorder
  - Hereditary absence or abnormalities of components of thromboxane pathway
    - Series of phospholipases catalyze the release of arachidonic acid and other compounds from membrane phospholipids
    - o Arichidonic acid is converted to intermediate prostaglandins by cyclooxygenase
    - $\circ$  Those intermediate prostaglandins are converted to thromboxane  $A_2$  by thromboxane synthase
    - Thromboxane A<sub>2</sub> (with other compounds) mobilizes calcium from internal stores into the cytoplasm initiating events leading to secretion and aggregation of platelets
  - Aspirin like defects

- 3. Inherited disorders of receptors and signaling pathways
  - Collagen Receptors defects (GP Ia/IIa or GP VI)
  - ADP Receptors defects (P2X<sub>1</sub>, P2Y<sub>1</sub> and P2Y<sub>12</sub>)
  - Epinephrine Receptor (α<sub>2</sub>-adrenergic receptor) defects
  - Scott syndrome
    - o Platelets do not transport phospholipids to outer membrane
    - o Platelet plug is not stabilized due to lack of fibrin
  - Stromorken syndrome
    - o Platelets always in activated state

# Thrombocytopenia and Thrombocytosis (Quantitative)

### **Thrombocytopenia**

- Platelet count < 100,000/uL (reference range 150,000 450,000/uL)
- Most common cause of clinically significant bleeding
- Impaired/Decreased Production
  - o Megakaryocyte hypoplasia in BM
  - o Congenital
    - Lack of adequate megakaryocytes or decreased thrombopoiesis
    - Fanconi anemia
      - pancytopenia
    - TAR syndrome
      - Rare autosomal recessive disorder
      - Neonatal thrombocytopenia (platelet count actually increases with age)
      - Hypoplasia of radial bones of forearms
      - Elevated WBC
    - Wiskott-Alderich
      - X linked
      - Bernard-Soulier
    - MYH9-Related Diseases (nonmuscle myosin heavy chain gene) –abnormal platelet size
      - May Hegglin anomaly
        - Autosomal dominant
        - Large platelets and thrombocytopenia (normal platelet activating agent responses)
        - Dohle-bodies in neutrophils
      - More rare: Sebastian syndrome, Fechtner syndrome and Epstein syndrome
    - Amegakaryocytic thrombocytopenia
      - autosomal recessive reflecting BM failure
      - Infants < 20,000 platelets at birth
      - Petichiae
      - Likely develop aplastic anemia before 1 year old
      - Reduced megakaryocyte progenitors and 

        TPO (TPO receptor function is lost)
    - Neonatal Thrombocytopenia
      - Many types
      - Causes:
        - o TORCH (toxoplasmosis, other (*Treponema pallidum*, varicella-zoster virus, parvovirus B19), rubella, cytomegalovirus [CMV], herpes)
        - Drug exposure in utero (sulfonamides)
        - o Decrease or absence of megakaryocytes in neonates
  - Acquired
    - Drugs
      - Chemotherapeutic agents
      - Ethanol ingestion (months to years of excessive use)
      - Interferon therapy

- o Ineffective thrombosis
  - Megaloblastic anemias
    - Thrombocytopenia caused by impaired DNA synthesis
    - Deformed megakaryocytes in BM
    - Large platelets in PB that have shortened survival time and abnormal function
- Viruses
- Bacteria
- Malignancy

### Increased Platelet Destruction

- o Immunologic responses
  - ITP
    - Idiopathic; no etiology
    - Acute
      - o Children 2-5 years
      - o Abrupt bruising, petechiae, mucosal bleeding
      - o 1-3 weeks after infection (upper respiratory or GI virus)
      - o self-limited
      - o 3-4% considered severe with <10,000 platelets
      - o binding of antibodies from previous infections to platelets
    - Chronic
      - o Most prevalent in women 20-50 years
      - o Mucocutaneous bleeding, menorrhagia, epistaxis, ecchymoses
      - Caused by autoantibodies attached to platelets → shortened platelet lifespan
      - o Increased platelet volume
    - Both chronic and acute will show abnormal platelet function test results
  - Drug induced
    - Quinidine/quinine/sulfonamide derivatives
      - Abrupt onset of bleeding symptoms
      - o Drug combines with antibody and binds platelets by Fab regions
      - Fc regions of immunoglobulin still available to bind to Fc receptors of phagocytic cells
      - o Platelet count drops rapidly and often may be <10,000/uL
    - Hapten- dependent
      - o Drug combines with a carrier molecule (usually plasma protein) to then act as a complete antigen
      - o Penicillin and penicillin derivatives
      - Platelet count rapidly declines and can be as low as <1,000/uL</li>
    - Drug induced autoantibodies
      - Drugs stimulate formation of autoantibody that binds platelet in absence of drug
    - HIT (Heparin-induced thrombocytopenia)
      - Binding of therapeutic heparin to platelet factor 4 (PF4) or binding of PF4 to the platelet membrane causes conformational change in PF4
      - This creates exposed necepitopes
      - The Fab portion of an IgG binds to the PF4 necepitope
      - The Fc portion of the IgG binds with the platelet FcγIIa receptor, leading to platelet activation and aggregation

- %-14 days after exposure to heparin, platelet counts rarely dip below 15,000/uL
  - Mild thrombocytopenia is more common
- NAIT
  - Neonatal alloimmune thrombocytopenia
  - Mother lacks platelet specific antigen that fetus inherits from father
  - She makes antibodies to that fetal antigen
  - Scattered petechiae and purpuric hemorrhage soon after birth
- Neonatal autoimmune
  - Passive transplacental transfer of antibodies from mother with ITP or systemic lupus erythematosus
- PTP
  - Post transfusion purpura
  - Plasma from recipient contain alloantibodies to antigens on platelets of transfused product
  - Multiparous middle aged women
- o Nonimmunologic Responses
  - Mechanical damage
    - platelet interaction to nonendothelial surfaces
  - Thrombocytopenia in pregnancy and preclampsia
  - Hemolytic Disease of the Newborn
  - TTP (Thrombotic Thrombocytopenic Purpura)
    - Moschcowitz syndrome
    - Microangiopathic hemolytic anemia
      - o Thrombocytopenia
      - Neurologic abnormalities
      - o Hemolysis usually sever (less than 10 mg/dL Hgb)
    - Directly related to accumulation of ultralarge von Willebrand factor (UL-VWF) multimers in the plasma
    - In normal plasma the UL-VWF multimers are rapidly cleaved into smaller VWF multimers by the VWF-cleaving protease ADAMTS13
    - Treatment: Therapeutic plasma exchange (TPE) with FFP
      - o 1st: some of UL-VWF removed by apheresis
      - o 2<sup>nd</sup>: plasma supplies the deficient ADAMTS13 protease
  - HUS (Hemolytic Uremic Syndrome)
    - Microangiopathic hemolytic anemia
    - more common than TTP
    - 90% of cases caused by *Shigella dysenteriae* serotypes or entrohemorrhagic *E. coli* OH serotypes (E. coli O157)
    - Toxins enter the bloodstream and attach to renal glomerular capillary endothelial cells
      - o become damaged/swollen and release UL-VWF
      - o can also be caused by certain drugs
    - Cardinal signs of HUS:
      - o Hemolytic anemia, renal failure, and thrombocytopenia
      - o Thrombocytopenia more mild in comparison to TTP

- DIC (Disseminated intravascular coagulation)
  - activation of coagulation cascade (many causes) resulting in a consumptive coagulopathy that entraps platelets in intravascular fibrin clots
  - similar to TTP including MAHA and deposition of thrombi in arterial circulation of most organs
  - DIC = red clots whereas TTP = white clots

#### Acute DIC

- Severe thrombocytopenia with decreased FV, FVIII and fibrinogen
- D-dimer is positive

#### **Chronic DIC**

- clotting factors may be slightly reduced or normal and compensatory thrombocytopoiesis results in lower to normal platelet counts
- D-dimer not usually elevated but can be slightly increased

### • Purpura Fulminans

- devastating thrombotic disorder (often acute and fatal)
- mirror symptoms of DIC
- can be presenting feature of acute sepsis from bacterial infection
  - o inflammatory response where coagulation and complement pathways are on overdrive which leads to increased bleeding

### **Thrombocytosis**

- Defined as abnormally high platelet count, typically >450,000/uL
- Reactive thrombocytosis used to describe elevation of platelet count secondary to inflammation
- Marked and persistent elevation in platelet count is hallmark of myeloproliferative disorders
- Reactive Thrombocytosis
  - o Platelet counts between 450,000 to 800,000/uL with no change in platelet function
    - Reactive Thrombocytosis Associated with Hemorrhage or Surgery
      - Platelet count can be low for 2-6 days but rebounds to slightly elevated levels
      - Normal levels by 10-16 days after the blood loss
    - Postsplenectomy Thrombocytosis
      - Platelet count can exceed 1 million/uL
      - Spleen normally sequesters 1/3 of circulating platelets at any given time
    - Thrombocytosis Associated with Iron Deficiency Anemia
      - Believed iron plays a role in regulating thrombopoiesis
      - Platelet count as high as 2 million have been seen in IDA with return to normal when iron treatment is administered
    - Thrombocytosis Associated with Inflammation and Disease
      - Similar to elevation in C-reactive protein, fibrinogen and VWF and other acute phase reactants
      - Kawasaki disease
        - Disorder caused by inflammation of the walls of small and medium-sized arteries throughout the body
    - Exercise-Induced Thrombocytosis
    - Rebound Thrombocytosis
- Thrombocytosis Associated with Myeloproliferative Disorders
  - o Common finding in four chronic myeloproliferative disorders including:
    - Polycythemia vera
    - Chronic myelogenous leukemia (CML)
    - Myelofibrosis with myeloid metaplasia (primary myelofibrosis)
    - Essential thrombocythemia (ET)
      - ET is a chronic myeloproliferative neoplasm
      - Most common cause of thrombocytosis when reactive thrombocytosis can be excluded
      - Platelets of 1 million/uL and proliferation of marrow megakaryocytes
      - Persistent elevation of platelet count is an absolute requirement for diagnosis
        - o ET presents with hemorrhage, platelet dysfunction and thrombosis
        - o Thrombosis in microvasculature or larger vasculature can occur
        - Lab Findings:
          - Platelet size is heterogeneous and platelets may be notable clumped on smears
          - Platelets may look agranular or hypogranular
          - Giant or misshapen platelets is common finding
          - Aggregation usually absent in response to EPI and ADP; Normal